Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | FGR | P09769 | 1/20 | 0.42 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.42 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.42 |
| ▸ | CSK | P41240 | 1/20 | 0.42 |
| ▸ | TXK | P42681 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086538 | 1.00 | TERT (0.49) | TERTDOT1LKDREGFRSYK | |
| SCHEMBL23906566 | 0.91 | TERT (0.49) | TERTDOT1LKDREGFRSYK | |
| SCHEMBL30086556 | 0.91 | TERT (0.49) | TERTDOT1LKDREGFRSYK | |
| SCHEMBL30086271 | 0.87 | TERT (0.47) | TERTDOT1LKDREGFRSYK | |
| SCHEMBL25261778 | 0.87 | TERT (0.47) | TERTDOT1LKDREGFRSYK | |
| SCHEMBL23887610 | 0.87 | ABL1 (0.51) | TERTDOT1LEGFRSYKNPC1 | |
| SCHEMBL30086592 | 0.87 | ABL1 (0.51) | TERTDOT1LEGFRSYKNPC1 | |
| SCHEMBL25225055 | 0.86 | AURKA (0.46) | TERTDOT1LEGFRSYKLYN | |
| SCHEMBL30086643 | 0.86 | AURKA (0.46) | TERTDOT1LEGFRSYKLYN | |
| SCHEMBL23887662 | 0.84 | KDR (0.47) | KDREGFRSYKJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | TERT 2562/4885DOT1L 2853/4885KDR 94/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | TERT 2562/4885DOT1L 2853/4885KDR 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.